Nanoscope Therapeutics Announces Positive Top-line Results from Randomized Controlled Trial of MCO-010 for Retinitis Pigmentosa

Contributed by: PR Newswire

Images

PR Newswire associated0

Tags

Nanoscope-Therapeutic

More Like This

Beacon Therapeutics Announces Positive Phase 2 Interim 6-Month Data from DAWN Trial of Laru-zova in Patients with X-linked Retinitis Pigmentosa (XLRP) at ARVO 2025

PR Newswire associated0

HUIDAGENE THERAPEUTICS ANNOUNCES FIRST PATIENT DOSED IN MULTINATIONAL PHASE 1/2 TRIAL OF HG004 FOR INHERITED BLINDNESS

Institute of Molecular and Clinical Ophthalmology Basel Spinout RhyGaze Closes USD 86 Million Series A Round to Further Novel Gene Therapy for Vision Restoration

Axovia Therapeutics Announces Three Upcoming Poster Presentations at ASGCT

Positive Niemann-Pick disease type C (NPC) and GM2 gangliosidosis data from nizubaglustat Phase 2 RAINBOW study conducted by Azafaros presented at major metabolic disease conference

A Race Against Blindness Announces $2 Million Grant to Support Sight-Saving Clinical Trial

Axovia Therapeutics Presents New Preclinical Data for AXV-101 for the Treatment of Blindness Associated with BBS Mutations at ASGCT

Axovia Therapeutics Unveils New Preclinical Data for AXV-201, for Treatment of Genetic Obesity Caused by MC4R Mutations, at ASGCT